Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a south african cohort with advanced HIV disease

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Ledwaba, Lotty ^a   Tavel, Jorge A ^b   Khabo, Paul ^a   Maja, Patrick ^a   Qin, Jing ^b   Sangweni, Phumele ^a   Liu, Xiao ^b   Follmann, Dean ^b   Metcalf, Julia A ^b   Orsega, Susan ^b   Baseler, Beth ^c   Neaton, James D ^d   Lane, H Clifford ^b   The Project Phidisa Biomarkers Team, ^e  

^a Project Phidisa   (South Africa)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c SAIC FREDERICK INC   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; D DIMER; DIDANOSINE; EFAVIRENZ; HIGH SENSITIVITY C REACTIVE PROTEIN; INTERLEUKIN 6; LAMIVUDINE; LOPINAVIR; RITONAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD CLOTTING; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SOUTH AFRICA; BLOOD; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; PHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; VIROLOGY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; BLOOD COAGULATION; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV; HIV INFECTIONS; HUMANS; INFLAMMATION; MALE; PROGNOSIS; SOUTH AFRICA; SURVIVAL RATE; VIRAL LOAD;

EID: 84863376913     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024243     Document Type: Article

References (33)

1. UNAIDS Website. Available: http://www.unaids.org/en/KnowledgeCentre/HIVData/CountryProgress/2010CountryProgressAllCountries.asp. Accessed 2011 Aug 20.
2. Lehohla PJ, Mid-year population estimates. Statistics South Africa (2009) Available: http://www.statssa.gov.za/Publications/statsdownload.asp?PPN=P0302&SCH=4437. Accessed 2011 Dec.
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1338: 853-60.
4. Michaels SH, Clark R, Kissinger P, (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection [Letter]. N Engl J Med 339: 405-6.
5. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, et al. (1998) Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infections duration. Multicenter AIDS Cohort Study Investigators. JAMA 280: 1497-503.
6. Spira R, Marimoutou C, Binquet C, Lacoste D, Dabis F, (1998) Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995-1997. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA). J Acquir Immune Defic Syndr Hum Retrovirol 18: 358-64.
7. Correll PK, Law MG, McDonald AM, Cooper DA, Kaldor JM, (1998) HIV disease progression in Australia in the time of combination antiretroviral therapies. Med J Aust 169: 469-72.
8. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski, et al. (1997) Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 11: 1731-8.
9. Sendi PP, Bucher HC, Craig BA, Pfluger D, Battegay M, (1999) Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 20: 376-81.
10. Gebhardt M, Rickenbach M, Egger M, (1998) Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland. Swiss HIV Cohort Study. AIDS 12: 1195-201.
11. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, et al. (1998) Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352: 1725-30.
12. Pezzotti P, Napoli PA, Acciai S, Boros S, Urciuoli R, et al. (1999) Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. Tuscany AIDS Study Group. AIDS pp. 13-249-55.
13. Walsh JC, Jones CD, Barnes EA, Gazzard BG, Mitchell SM, (1998) Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors. AIDS 12: 613-8.
14. Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, et al. (1999) HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52: 623-5.
15. World Health Organization, 'Universal Access by 2010', Available: http://www.who.int/hiv/data/en/. Accessed 2011 Apr 1.
16. Egger M for The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) Groups (2006) Mortality of HIV-1 infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-24.
17. Marazzi MC, Liotta G, Germano P, Guidotti G, Altan AD, et al. (2008) Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses 24: 555-60.
18. Johanessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, et al. (2008) Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infectious Disease 8 (52): 1471-2334.
19. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296: 782-793.
20. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R, (2005) Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 19: 2141-2148.
21. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, et al. (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20: 1181-9.
22. Egger M, May M, Chene G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360 (9327): 119-29.
23. Palella FJ, Baker R, Moorman AC, Chmiel JS, Wood KC, et al. (2006) Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study. J Acquired Immun Defic Syndr 43 (1): 27-34.
24. El-Sadar WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, et al. (2006) CD4 count guided interruption of antiretroviral treatment. NEJM 355 (22): 2283-96.
25. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, et al. (2008) Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV infection. PloS Medicine 5 (10): 1496-1508.
26. Neuhaus J, Angus B, Kowalska JD, La Rosa A, Sampson J, et al. (2010) Risk for all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 24: 697-706.
27. Phillips AN, Neaton J, Lundgren JD, (2008) The role of HIV in serious diseases other than AIDS. AIDS 22: 409-418.
28. Morcroft A, Reiss P, Gasoirowski J, Ledergerber B, Chiesi A, et al. (2009) Serious fatal and non fatal non-AIDS defining illnesses in Europe. Proceedings of the conference on retroviruses and co-infection; San Francisco, California, USA.
29. Jong E, Louw S, van Gorp E, Meijers J, ten Cate H, et al. (2010) The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals. Thrombosis and Haemostasis 104 (6): 1228-1234.
30. Ratsela A, for the Phidisa 2 Study Group (2010) A randomized factorial trial comparing 4 treatment regimens in treatment-naïve HIV-infected persons with AIDS and/or <200 CD4+ T cells/mm3 in South Africa. J Infect Dis 202 (10): 1529-37.
31. Neuhaus J, Jacobs DR, Baker JV, Calmy A, Duprez D, et al. (2010) Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 201 (12): 1788-1795.
32. Cohen HJ, Harris T, Piper CF, (2003) Coagulation and activation of inflammatory pathways in the development of function decline and mortality in the elderly. Am J Med 114: 180-187.
33. Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS, (2002) D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest 121: 1262-1268.